SANTA MONICA, Calif., November 6, 2025 - BlackRock TCP Capital Corp. ("we," "us," "our," "TCPC" or the "Company"), a business development company (NASDAQ: TCPC), today announced its financial results for the third quarter ended September 30, 2025 and filed its Form 10-Q with the U.S. Securities and Exchange Commission. Exhibit 99.1 BLACKROCK TCP CAPITAL CORP. ANNOUNCES THIRD QUARTER 2025 FINANCIAL RESULTS INCLUDING NET INVESTMENT INCOME OF $0.32 PER SHARE; DECLARES A FOURTH QUARTER DIVIDEND OF $0.25 PER SHA ...

EXHIBIT 99.1 "The third quarter was marked by executional focus, and we remain on track with our planned IND filings for HWK-007 and HWK-016 by the end of the year. We continue to deploy capital efficiently, maintaining strong financial discipline as we prepare to enter the clinic and deliver potentially value-creating milestones," said Dave Lennon, PhD, President and CEO of Whitehawk Therapeutics. "I'm proud of our role in adding to the scientific understanding of PTK7 with the data we presented at AACR-NC ...

Exhibit 99.1 Lifetime Brands, Inc. Reports Third Quarter 2025 Financial Results Strong Cost Controls and Project Concord Aiding Performance Company Well Positioned to Capitalize on Industry Dislocation GARDEN CITY, NY, November 6, 2025 – Lifetime Brands, Inc. (NasdaqGS: LCUT), a leading global designer, developer and marketer of a broad range of branded consumer products used in the home, today reported its financial results for the quarter ended September 30, 2025. Rob Kay, Lifetime's Chief Executive Offic ...

"Q3 continued our positive momentum, with strong revenue, adjusted EBITDA and bookings growth," said Thomas Warsop, president and CEO of ACI. "Year-to-date, both Payment Software and Biller segment revenues have grown 12%. In Q3, we signed our first ACI Connetic customer and are encouraged by the early interest and demand for this industry-leading, cloud-native payments platform. Just recently, we hosted Payments Unleashed, ACI's premier summit, bringing together thought leaders, innovators and visionaries ...

Vericel Corporation 64 Sidney Street Cambridge, MA 02139 T (617) 588-5555 F (617) 588-5554 www.vcel.com Vericel Reports Third Quarter 2025 Financial Results Record Third Quarter Total Revenue of $67.5 Million MACI Revenue Growth of 25% to $55.7 Million Exhibit 99.1 Net Income of $5.1 Million and Adjusted EBITDA Margin of 25% Record Third Quarter Operating Cash Flow of $22.1 Million More than 800 MACI Arthro Surgeons Trained to Date Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., November 6, 2 ...

"We have considerable momentum heading into the end of the year. We see tremendous potential for ozureprubart in large IgE-driven indications such as food allergy and CSU, and our recent financing gives us additional capital to advance our programs," said Brian Wong, President and CEO of RAPT. "Looking ahead, we plan to report topline results from Jeyou's Phase 2 trial of ozureprubart in asthma and to provide additional details from the recently reported Phase 2 clinical trial in CSU at a medical meeting ne ...

Exhibit 99.1 Playtika Holding Corp. Reports Q3 2025 Financial Results Revenue of $674.6 million and Direct-to-Consumer ("DTC") Revenue of $209.3 million Revenue Decreased (3.1)% Sequentially and Increased 8.7% Year Over Year DTC Platforms Revenue Increased 19.0% Sequentially and 20.0% Year Over Year Herzliya, Israel - November 6, 2025 - Playtika Holding Corp. (NASDAQ: PLTK) today released financial results for its third quarter for the period ending September 30, 2025. Financial Highlights "As we close 2025 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 UROGEN PHARMA LTD. (Exact Name of Registrant as Specified in its Charter) For the transition period from to Commission file number: 001-38079 (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FORM 10-Q (State or other jurisdiction of incorporation ...

Exhibit 99.1 There can be no assurance that the process will result in any such transaction. VYNE's Board of Directors has not set a timetable for the strategic review process. VYNE does not intend to provide updates until the Board approves a specific action or otherwise determines that disclosure is appropriate or required. The Company has engaged LifeSci Capital as a financial advisor to assist in the strategic review process. Pipeline Overview VYN202, an oral small molecule BD2-selective BET inhibitor: ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended September 30, 2025 ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Transition Period From ____ to ____ Commission File Number: 814-00899 BLACKROCK TCP CAPITAL CORP. (Exact Name of Registrant as Specified in its Charter) Delaware 56-2594706 (S ...